Importance: Hair loss, or alopecia, is one of the most commonly presented problems in dermatology. Scarring alopecias are considered particularly damaging due to limited success in slowing permanent disease progression, and current treatment methods, such as intralesional and topical steroids and topical minoxidil, are largely ineffective. Objective: Hair transplantation is a debated treatment option for advanced cases of primary scarring alopecia. This study reviews the efficacy of hair transplantation as a treatment option for primary scarring alopecia. Evidence Review: A primary literature search was conducted using PubMed to identify articles in scarring alopecia and hair transplants published from 1960 to the present time. Findings: Fifteen reports with 34 patients were included in this review. Twenty six patients experienced moderate to positive results, while 8 patients experienced negative results or recurrence of disease. Positive hair transplantation results have been reported in patients with central centrifugal cicatricial alopecia, en coup de sabre, discoid lupus erythematous, pseudopelade de brocq, and folliculitis decalvans. Positive and -negative results were observed in patients with lichen planopilaris and frontal fibrosing alopecia. Conclusion and Relevance: Findings show that hair transplant surgery can be considered as a treatment option for certain primary scarring alopecias. However, data must be interpreted with caution due to concern for positive-result publication bias.

1.
Rongioletti F, Christana K: Cicatricial (scarring) alopecias: an overview of pathogenesis, classification, diagnosis, and treatment. Am J Clin Dermatol 2012; 13: 247–260.
2.
Filbrandt R, Rufaut N, Jones L, Sinclair R: Primary cicatricial alopecia: diagnosis and treatment. CMAJ 2013; 185: 1579–1585.
3.
Mobini N, Tam S, Kamino H: Possible role of the bulge region in the pathogenesis of inflammatory scarring alopecia: lichen planopilaris as the prototype. J Cutan Pathol 2005; 32: 675–679.
4.
Rigopoulos D, Stamatios G, Ioannides D: Primary scarring alopecias. Curr Probl Dermatol 2015; 47: 76–86.
5.
Gordon KA,Tosti A: Alopecia: evaluation and treatment. Clin Cosmet Investig Dermatol 2011; 4: 101–106.
6.
Unger W, Unger R, Wesley C: The surgical treatment of cicatricial alopecia. Dermatol Ther 2008; 21: 295–311.
7.
Gho CG, Neumann HA: The influence of preservation solution on the viability of grafts in hair transplantation surgery. Plast Reconstr Surg Glob Open 2013; 1:e90.
8.
Loganathan E, et al: Complications of hair restoration surgery: a retrospective analysis. Int J Trichology 2014; 6: 168–172.
9.
Callender VD, Lawson CN, Onwudiwe OC: Hair transplantation in the surgical treatment of central centrifugal cicatricial alopecia. Dermatol Surg 2014; 40: 1125–1131.
10.
Howick J, et al: (Oxford Centre for Evidence-Based Medicine, 5653).
11.
Tyagi V, Singh PK: A new approach to treating scarring alopecia by hair transplantation and topical minoxidil. Indian J Dermatol Venereol Leprol 2010; 76: 215.
12.
Dai Y, Xu AE, He J: A case report of coup de sabre patient with hair transplantation. J Dermatolog Treat 2017; 28: 546–548.
13.
Park SW, Wang HY: Survival of grafts in coup de sabre. Dermatol Surg 2002; 28: 763–766; discussion 766–767.
14.
Nordström RE: Hair transplantation. The use of hairbearing compound grafts for correction of alopecia due to chronic discoid lupus erythematosus, traumatic alopecia, and male pattern baldness. Scand J Plast Reconstr Surg Suppl 1976; 14: 1–37.
15.
Liu YS, Jee SH, Chan JL: Hair transplantation for the treatment of lichen planopilaris and frontal fibrosing alopecia: a report of two cases. Australas J Dermatol 2018; 59:e118–e122.
16.
Podda M, Spieth K, Kaufmann R: Er:YAG laser-assisted hair transplantation in cicatricial alopecia. Dermatol Surg 2000; 26: 1010–1014.
17.
Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR: A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol 2007; 57: 47–53.
18.
Saxena K, Saxena DK, Savant SS: Successful hair transplant outcome in cicatricial lichen planus of the scalp by combining scalp and beard hair along with platelet rich plasma. J Cutan Aesthet Surg 2016; 9: 51–55.
19.
Rogers N: Imposters of androgenetic alopecia: diagnostic pearls for the hair restoration surgeon. Facial Plast Surg Clin North Am 2013; 21: 325–334.
20.
Jiménez F, Poblet E: Is hair transplantation indicated in frontal fibrosing alopecia? The results of test grafting in three patients. Dermatol Surg 2013; 39: 1115–1118.
21.
Nusbaum BP, Nusbaum AG: Frontal fibrosing alopecia in a man: results of follicular unit test grafting. Dermatol Surg 2010; 36: 959–962.
22.
Cranwell WC, Sinclair R: Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation. Australas J Dermatol 2017; 58:e94–e96.
23.
Ross EK, Tan E, Shapiro J: Update on primary cicatricial alopecias. J Am Acad Dermatol 2005; 53: 1–37; quiz 38–40.
24.
Stough DB, Berger RA, Orentreich N: Surgical improvement of cicatricial alopecia of diverse etiology. Arch Dermatol 1968; 97: 331–334.
25.
Moreno-Arias GA, Izento-Menezes CM, Camps-Fresneda A, Carrasco MA: Scarring alopecia: case study. Dermatol Surg 2002; 28: 360–362.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.